COMP <GO>
ZBH vs EW // EV/EBITDA & P/E VALUATION
Zimmer Biomet Holdings Inc. (NYSE) VS. Edwards Lifesciences Corporation (NYSE) • 15-METRIC TALLY: ZBH 4
— EW 9
▲ EV/EBITDA & P/E VALUATION LEADER: ZBH
LAST: $94.52 (-3.03%) • MKT CAP: $18.03B
valuation
19.3x
LAST: $92.01 (-2.57%) • MKT CAP: $53.03B
valuation
35.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZBH VS. EW)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZBH | EW | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.70% | 78.00% | -8.30 | EW | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.60% | 12.50% | -7.90 | EW | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.3x | 35.1x | -15.80 | ZBH | /valuation <GO> |
| Free Cash Flow Yield | 7.92% | 2.45% | +5.47 | ZBH | /fcf-yield <GO> |
| Operating Margin | 13.30% | 20.80% | -7.50 | EW | /operating-margins <GO> |
| Net Profit Margin | 8.60% | 17.70% | -9.10 | EW | /net-margins <GO> |
| Revenue Growth (YoY) | 7.20% | 11.50% | -4.30 | EW | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.02% | 0.00% | +1.02 | ZBH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.42 | 12.36 | -9.94 | EW | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.8 | 56.5 | -7.70 | EW | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 1.08 | -0.06 | EW | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.6x | 47.2x | -22.60 | ZBH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.03B | $53.03B | -$35.01B | EW | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZBH REV | EW REV | ZBH GROSS % | EW GROSS % | ZBH FCF | EW FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.23B | $6.07B | 69.7% | 78.0% | $1.47B | $1.33B |
| FY 2024 | $7.68B | $5.44B | 71.5% | 79.5% | $1.30B | $289.9M |
| FY 2023 | $7.39B | $5.01B | — | — | $1.25B | $670.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZBH // BETA 1.02
EW // BETA 1.08